BR9408450A
(pt)
*
|
1993-12-29 |
1997-08-05 |
Pfizer |
Antagonistas da neuroquinina diazabiciclicos
|
FR2786770B1
(fr)
*
|
1998-12-04 |
2001-01-19 |
Synthelabo |
Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
|
AU7552401A
(en)
*
|
2000-06-12 |
2001-12-24 |
Univ Rochester |
Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
|
FR2812635B1
(fr)
*
|
2000-08-01 |
2002-10-11 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
|
SE0003795D0
(sv)
*
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Pharmaceutically useful compounds
|
FR2825705B1
(fr)
*
|
2001-06-08 |
2005-05-20 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
|
FR2835186B1
(fr)
*
|
2002-01-28 |
2006-10-20 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
|
FR2844273B1
(fr)
|
2002-09-05 |
2008-04-04 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
|
FR2848210B1
(fr)
*
|
2002-12-06 |
2007-10-19 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
|
US7439253B2
(en)
|
2002-12-06 |
2008-10-21 |
Novexel |
Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
|
MX2007000428A
(es)
|
2004-07-15 |
2008-03-05 |
Amr Technology Inc |
Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
US20060281670A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Wisconsin Alumni Research Foundation (Warf) |
Compositions and methods for modulating angiogenesis
|
CA2615403C
(en)
|
2005-07-15 |
2015-06-16 |
Amr Technology, Inc. |
Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
AU2006297443B2
(en)
|
2005-09-29 |
2010-08-12 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
TWI404532B
(zh)
*
|
2006-11-02 |
2013-08-11 |
Targacept Inc |
菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
|
EP2109608B1
(en)
|
2007-01-10 |
2011-03-23 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
US8106086B2
(en)
|
2007-04-02 |
2012-01-31 |
Msd K.K. |
Indoledione derivative
|
JP5501227B2
(ja)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
|
JP5038509B2
(ja)
|
2008-01-18 |
2012-10-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
β−ラクタマーゼ阻害剤
|
AU2009222122A1
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
ES2662072T3
(es)
|
2009-05-12 |
2018-04-05 |
Albany Molecular Research, Inc. |
7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
|
KR20120034644A
(ko)
|
2009-05-12 |
2012-04-12 |
알바니 몰레큘라 리써치, 인크. |
아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
|
EP2429293B1
(en)
|
2009-05-12 |
2014-10-29 |
Bristol-Myers Squibb Company |
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
|
FR2951171A1
(fr)
*
|
2009-10-09 |
2011-04-15 |
Novexel |
Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
|
KR101485645B1
(ko)
|
2009-10-14 |
2015-01-22 |
머크 샤프 앤드 돔 코포레이션 |
p53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CN107090456B
(zh)
|
2010-08-02 |
2022-01-18 |
瑟纳治疗公司 |
使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
DK2657234T3
(da)
*
|
2010-12-22 |
2017-02-20 |
Meiji Seika Pharma Co Ltd |
Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
BR112013028813B1
(pt)
*
|
2011-08-27 |
2020-10-20 |
Wockhardt Limited |
derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
|
BR112013032974A2
(pt)
*
|
2011-08-30 |
2016-09-06 |
Wockhardt Ltd |
"derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
|
WO2013038330A1
(en)
*
|
2011-09-13 |
2013-03-21 |
Wockhardt Limited |
Nitrogen containing compounds and their use
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
AR090539A1
(es)
*
|
2012-04-02 |
2014-11-19 |
Astrazeneca Ab |
COMPUESTOS INHIBIDORES DE b LACTAMASA
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
MX366948B
(es)
*
|
2012-05-30 |
2019-07-30 |
Meiji Seika Pharma Co Ltd |
Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
|
CA2882950A1
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2919788A4
(en)
|
2012-11-14 |
2016-05-25 |
Univ Johns Hopkins |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
|
LT2925888T
(lt)
|
2012-11-28 |
2018-01-10 |
Merck Sharp & Dohme Corp. |
Vėžio gydymo kompozicijos ir būdai
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
US9624222B2
(en)
*
|
2013-03-08 |
2017-04-18 |
Wockhardt Limited |
Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octance
|
MX2015011722A
(es)
*
|
2013-03-08 |
2015-12-03 |
Wockhardt Ltd |
Proceso para la preparacion de (2s, 5r)-7-oxo-6-sulfooxi-2-[((3r)- piperidin-3-carbonil)carbonil hidrazino]-1,6-diaza-biciclo[3.2.1] octano.
|
AU2013399862B2
(en)
*
|
2013-03-08 |
2016-07-14 |
Wockhardt Limited |
A process for preparation of (2S, 5R)- sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
|
JP6285968B2
(ja)
*
|
2013-03-08 |
2018-02-28 |
ウォックハート リミテッド |
(2s,5r)−6−ベンジルオキシ−7−オキソ−1,6−ジアザ−ビシクロ[3.2.1]オクタン−2−カルボン酸のナトリウム塩およびその調製
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
MX367578B
(es)
*
|
2013-09-24 |
2019-08-27 |
Meiji Seika Pharma Co Ltd |
Proceso para producir derivado de diazabiciclooctano y su intermediario.
|
SI3221313T1
(sl)
|
2014-11-17 |
2019-04-30 |
Entasis Therapeutics Limited |
Kombinacijska terapija za zdravljenje okužb z rezistentnimi bakterijami
|
CN107438614B
(zh)
|
2015-04-03 |
2020-01-31 |
拜欧蒂姆公司 |
杂环化合物及它们在预防或治疗细菌感染中的应用
|
JP6997178B2
(ja)
|
2016-09-16 |
2022-02-03 |
エンタシス・セラピューティックス・リミテッド |
ベータラクタマーゼ阻害剤化合物
|
BR112019023130A2
(pt)
|
2017-05-08 |
2020-05-26 |
Entasis Therapeutics, Inc. |
Compostos e métodos para tratamento de infecções bacterianas
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
CN108610313B
(zh)
*
|
2018-06-08 |
2022-03-04 |
三峡大学 |
一种酶抑制剂及其应用
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|